Navigation Links
Henry Ford Hospital: Unique Patient Study -- No Informed Consent
Date:5/8/2009

DETROIT, May 8 /PRNewswire/ -- Henry Ford Hospital is embarking on an unusual study intending to reduce brain damage or death of patients resulting from prolonged seizures before arriving at the hospital.

But because the patients are unconscious during the seizure, they will not be able to provide informed consent to participate in the study.

The Food and Drug Administration created regulations for research to be performed during emergency conditions without informed consent of the participant. Once patients awaken from the seizure their consent will be sought to continue in the study.

The study will involve patients with seizures lasting longer than five minutes that are being transported by EMS. Stopping the seizure as soon as possible is important to prevent brain-damage or death. Often the underlying cause of the seizure is unknown, but some causes include previous trauma, stroke, tumor, or infection.

The study, called RAMPART, will compare an intramuscular injection of midazolam (Versed) to an intravenous (IV) dose of lorazepam (Ativan). Both drugs are better than the most common current prehospital treatment for seizure, IV diazepam (Valium). The goal is to determine if an auto-injector with midazolam can stop seizures as fast as starting an IV and giving lorazepam.

The benefits include shorter seizures, more rapid drug administration, development of an auto-injector that could be used by non-medical personnel, and avoidance of multiple IV attempts on a seizing patient.

The three-year RAMPART study is being conducted at 17 centers around the United States. It is coordinated by the University of Michigan and funded by the National Institute of Neurological Diseases and Stroke which is a part of the National Institute of Health. Wayne State University/Detroit Medical Center is also participating in RAMPART.

The study will be conducted in conjunction with Detroit EMS. Any patient that is actively seizing upon arrival may be eligible to participate in the study. The patients must meet the inclusion and exclusion criteria of the study and be transported to either Henry Ford Hospital, Detroit Receiving Hospital, or Sinai-Grace Hospital to be included in the study. Other hospitals may be added later.

The Henry Ford Hospital Institutional Review Board (IRB) will review and monitor the study. Taher Vohra, M.D. and Christopher Lewandowski, M.D., both of the Department of Emergency Medicine at Henry Ford Hospital, are currently meeting with community groups to get their opinions on the study. Following these meetings, the Henry Ford Hospital IRB will review the process and determine final approval to conduct the study. The study is expected to start this summer.

For more information please visit www.detroitrampart.org.


'/>"/>
SOURCE Henry Ford Hospital
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Grosse Pointes Cottage Hospital Joins Henry Ford Health System
2. CNS Response, Inc. Names Henry T. Harbin, MD to Board of Directors
3. Fund-Raiser for Henry Ford Hospitals Stroke Program
4. Program for Stroke Survivors and Friends Hosted by Henry Ford Hospital
5. Repligen Elects Earl Henry, M.D. to the Board of Directors
6. Michigan Quality Council (MQC) Names Henry Ford Health System 2007 State Quality Award Recipient
7. AAPD to Present 2008 Henry B. Betts Award to International Human Rights Disability Advocate Eric Rosenthal
8. Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Henry Schein Medical Systems MicroMD(R) EMR 5.0
9. Henry Ford Hospital expands research on gene and radiation therapy for prostate cancer
10. Henry Ford Hospital to study effectiveness of a new procedure that may help emphysema suffers
11. Stella Mora Henry to Present The Eldercare Handbook at Aging in America Joint Conference of National Council on Aging & The American Society on Aging March 27-29
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce that ... Mr. Still was selected through a careful months-long search by the RBMA Board of ... our members, has been a part of building the RBMA since 1992,” said RBMA ...
(Date:3/28/2017)... ... ... With less than 10,000 dermatologists in the United States and more than ... the desire to conquer breakouts and eliminate skincare stress is widespread. Curology , ... released its inaugural survey on the State of Acne in America. , The ...
(Date:3/28/2017)... ... March 28, 2017 , ... A minimally invasive ... “perfect smile.” The National Association of Dental Laboratories (NADL) is informing dentists about ... aware of when utilizing dental laboratories and technicians that create these veneers. ...
(Date:3/28/2017)... ... March 28, 2017 , ... With expansion and efficiency ... in early March. , The seed processing plant opened in Marshallville in 2006, and ... The new office allows opportunity for transition of Patten Seed operations to the Middle ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... “A Prophets Bones”: a thrilling adventure that ... Donald Quinn. , “There were things that his parents and teachers had asked of him ... way that he was going to defy the Almighty Creator. There were some who would ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... New York , March 28, 2017 ... a largely consolidated vendor landscape, with the top three ... Agilent Technologies accounting for a significant 49% of the ... a recent report. The vendor landscape is intensely competitive ... share in the overall market. These factors have restricted ...
(Date:3/28/2017)... and TEL AVIV, Israel , March 28, ... in Israel . This new business entity, Emosis ... mostly dedicated to research and development of novel assays complementing the ... also, when relevant, locally support commercialization and sales development of Emosis ... This strategic ...
(Date:3/28/2017)... 2017  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a ... and other unmet medical needs, announced today two ... Research annual meeting.  The first poster to be ... of ENMD-2076 in Combination with Anti-PD1 in Syngeneic ... be presented on April 4 is entitled " ...
Breaking Medicine Technology: